MedTrace Logo

Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections

NCT06048692 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2023-09-21

No results posted yet for this study

Summary

the aim of this study is to evaluate the efficacy of employing cefepime (CFM) versus ampicillin/sulbactam (AMS) in lowering the rate of post-cesarean surgical site infections.

Conditions

  • Cesarean Section; Infection

Interventions

DRUG

Cefepime 1000 MG

Cefepime is a fourth-generation cephalosporin antibiotic

DRUG

Ampicillin-sulbactam

Broad-Spectrum Antibiotic

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Beni-Suef University · Faculty of Medicine Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-09-15
Completion
2023-09-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06048692 on ClinicalTrials.gov